Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (15588)	12/2/1999 10:56:00 AM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

IMON could well see new high later, it has momo'd to $15 on news before.

To: SSP who wrote (15588)	12/2/1999 11:10:00 AM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

CDNO up as GP at .045 all in should be sitting on free, or very cheap shares now.

To: SSP who wrote (15588)	12/2/1999 11:30:00 AM
From: Jim Bishop	Respond to of 150070

JOES time to eat a JOES again. Check this target, plus the chart looks great. ONZA mailing it too. Stockreporter Announces Investment Opinion on Eat At Joe's Ltd. NEW YORK, Dec 2, 1999 (BUSINESS WIRE) -- Stockreporter Begins Coverage of Eat At Joe's Ltd. (JOES) With a Strong BUY Recommendation and a Conservative Year 2000 Price Target of $7.20 Per Share Eat at Joe's Ltd. (OTC BB: JOES ) today received a strong buy recommendation from Stockreporter, a leading European financial Internet publication located at www.stockreporter.de . Stockreporter specializes in the coverage of micro-cap stocks and undervalued OTC and BB companies. The successful Stockreporter team is one of the first independent analysts to begin coverage of Eat at Joe's and release an investment opinion. Stockreporter began coverage with a conservative target price of $7.20 per share for the year 2000, thus indicating tremendous potential from a current share price of roughly $0.30 for investors to generate above average returns in the short, medium and long-term. "We are extremely pleased to initiate coverage of Eat at Joe's Ltd. with a strong buy recommendation for investors interested in above average shareholder returns," Torsten Prochnow from Stockreporter said. "Given that the Company intends to close several acquisitions by year-end, early investors stand to profit from tremendous short-term potential with upside pressure on JOES stock expected to be phenomenal right around New Years." "We are also projecting substantial long-term returns for investors with our year 2000 $7.20 per share price target," Prochnow continued. "Given the unique and successful nature of the 1950s style diner that Eat at Joe's is rolling out across the country, coupled with its early market lead in the $8 billion diner sector, we project that the value of JOES shares will continue to increase dramatically throughout the year 2000." A comparison to the Company's industry and sector as well as the overall S&P 500 provide further confirmation of the steep discount at which Eat at Joe's shares are trading. In fact, JOES is trading at a mere 0.99 price to sales (P/S) ratio for the trailing 12 months. This is far below the industry at a 3.78 P/S ratio, the sector at a 7.59 P/S ratio, and the S&P 500 at a 6.12 P/S ratio. The Company's 1.15 price to book (P/B) ratio for the most recent quarter is also well under the industry, sector and S&P 500 at P/B ratios of 5.71, 6.96 and 9.76, respectively. Therefore Stockreporter concludes that JOES' current stock price of roughly $0.30 per share represents a very attractive buying opportunity for investors looking to profit from the explosive nature of the diner restaurant segment. Stockreporter is very confident that Eat at Joe's shares will appreciate from today's undervalued levels and will offer investors some of the greatest profit opportunities in the small-cap arena over the short, medium, and long terms. The complete JOES report issued by Stockreporter is available in English and German and can be accessed at www.stockreporter.de . Furthermore highlights of the JOES buy recommendation will also appear in Barron's Magazine this Saturday, December 4th, and will also be featured on the highly frequented Barron's-Dow Jones website at www.barrons.com . NOTICE All Stockreporter recommendations are made on an unsolicited basis. The complete recommendation and additional information (e.g. forthcoming interviews with the CEO and the President) can be accessed on Stockreporter's website at www.stockreporter.de, which is currently the No. 1 micro-cap and OTC BB site in Europe, especially in Germany. The site is completely available in both the German and English languages. Stockreporter meticulously and independently selects the companies that are candidates for a buy recommendation and which are featured on the Stockreporter website. Any Stockreporter micro-cap recommendation still includes a high degree of risk and is at the investor's individual and own risk. Many Stockreporter recommendations contain forms of "forward-looking statements" that are based on the company's beliefs as well as assumptions made by information currently available to Stockreporter and to the general public. Such statements are subject to certain risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results will vary materially from those anticipated, estimated, or projected and the variations may be material. Therefore, no claim for any kind of warranty can and will be accepted by Stockreporter. Moreover, the team of Stockreporter wants to stress once again that all our buy recommendations are based on subjective assessments that have been made exclusively on the basis of facts being known to the general public. If you have any further questions regarding this buy recommendation or any other inquiry or suggestion, please do not hesitate to contact Stockreporter at any time. We are very interested in maintaining close contact with both institutional and private investors as well as OTC and BB companies.